Roche Holding Ltd vs AbbVie Inc.
A head-to-head of Roche Holding Ltd (RHHBY) and AbbVie Inc. (ABBV) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | RHHBY | ABBV |
|---|---|---|
| Market Cap | $331.13B | $453.11B |
| P/E (TTM) | 2.52 | 126.16 |
| Forward P/E | 15.75 | 15.63 |
| P/S | 5.19 | 5.66 |
| P/B | 0.96 | -57.26 |
| EV/EBITDA | 12.63 | 24.76 |
| Dividend Yield | 3.04% | 2.50% |
| Profit Margin | 20.33% | 5.79% |
| Gross Margin | 73.73% | 70.24% |
| Operating Margin | 29.16% | 32.85% |
| Revenue Growth (YoY) | -0.40% | +12.43% |
| FCF Yield | — | 5.62% |
| Debt / Equity | 81.15 | — |
| Current Ratio | 1.38 | 0.80 |
Which is better: Roche Holding Ltd or AbbVie Inc.?
- ✓Larger by market cap: AbbVie Inc.
- ✓Cheaper valuation (lower P/E): Roche Holding Ltd
- ✓Higher dividend yield: Roche Holding Ltd
- ✓More profitable (net margin): Roche Holding Ltd
- ✓Faster revenue growth: AbbVie Inc.
Across 10 available metrics, Roche Holding Ltd leads 7–3.
There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.
Share:
Compare Roche Holding Ltd with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.